欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
目的：探讨Hyper-CVAD/MA方案治疗复发或难治弥漫大B细胞淋巴瘤（diffuse large B-cell lymphoma,DLBCL）的疗效及安全性。方法：观察26例经系统化疗后复发或难治的DLBCL患者接受Hyper-CVAD/MA方案化疗,21-28天为1周期,连续2个周期评价疗效及安全性,分析生存情况。结果：全组26例患者中,总有效率为46.15%,其中完全缓解（complete remission,CR）3例（11.54%）,部分缓解（partial remission,PR）9例（34.61%）,全组患者中位生存时间为10（2-25）个月,1年和2年总生存率分别为28.57%、14.29%。不良反应主要表现为III-IV度骨髓抑制及继发的肺部感染,其他包括胃肠道反应、口腔炎、肝功能异常等。结论：Hyper-CVAD/MA治疗复发难治DLBCL有一定的疗效,且患者可耐受,可作为二线方案的一个选择。
英文摘要：
Objective： To evaluate the clinical efficacy and safety of Hyper-CVAD/MA regimen in patients with recurrent or refractory diffuse large B-cell lymphoma（DLBCL）. Methods： All 26 patients with recurrent or refractory DLBCL were treated with Hyper-CVAD/MA regimen after routine treatment. 21-28 days consisted of one cycle, and the therapeutic efficacy and adverse effect were observed after two cycles. Results： In 26 cases, the overall response rate was 46.15 %. Three patients（11.54 %） achieved a complete remission and 9（34.61 %） achieved a partial remission. The median time of the OS（overall survival） was 10 months. The one-year OS rate and two-year OS rate were 28.57 % and 14.29 %, respectively. Myelosuppression and infection were the major adverse reaction.Other side effects included gastroenteric reactions, oral mucosa inflammation, damage of live function was also observed. Conclusions：Hyper-CVAD/MA regimen can achieve a satisfied result in the treatment of recurrent or refractory DLBCL, and the toxicity was tolerable.
同期刊论文项目
同项目期刊论文
期刊信息
位置：